Venlafaxine Hydrochloride Extended-Release Tablets are indicated for Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD), as defined by DSM-IV. Efficacy in MDD was demonstrated in short-term and longer-term trials, with a mean dose of 136 mg/day. SAD treatment efficacy was established in short-term trials. The mechanism of action involves potent inhibition of neuronal serotonin and norepinephrine reuptake, with a weak effect on dopamine reuptake. The drug has no significant affinity for muscarinic cholinergic, H1-histaminergic, or α1-adrenergic receptors. Steady-state concentrations are attained within 3 days, with a linear pharmacokinetic profile. The absolute bioavailability is approximately 45%. Absorption is well-established, with ODV as the major active metabolite. Venlafaxine Hydrochloride Extended-Release Tablets are administered once daily with food, typically starting at 75 mg/day, with potential dose increases up to 225 mg/day for MDD and 75 mg/day for SAD. Clinical studies demonstrated superiority over placebo in MDD across multiple HAM-D measures and CGI scores. In longer-term studies, patients responding to an open-label trial continued on the same dose or switched to placebo for up to 26 weeks, maintaining response. Discontinuation should be gradual and individualized.